Literature DB >> 2327758

Guinea pig model for antibiotic transport across gastric mucosa: inhibitory tissue concentrations of clindamycin against Helicobacter pylori (Campylobacter pylori) following two separate dose regimens.

T U Westblom1, D E Duriex, E Madan, R B Belshe.   

Abstract

An animal model for antibiotic secretion across gastric mucosa was developed using adult guinea pigs. Antibiotics were given intramuscularly, and levels in serum and gastric mucosa were measured by high-pressure liquid chromatography at 1, 2, 4, 6, and 8 h postinjection. Mucosal levels of the drugs were measured in the superficial luminal portion of the mucosa, which was removed by mechanical scraping. Clindamycin levels were measured after doses of 10 and 100 mg/kg of body weight. After doses of 100 mg/kg, levels in serum peaked at 15.95 micrograms/ml at 2 h. Gastric mucosa showed a bimodal concentration curve with peaks of 15.91 micrograms/g at 1 h and 25.07 micrograms/g at 4 h. Concentrations in mucosa remained high when levels in serum fell, showing a mucosa/serum ratio of 87.70 after 8 h. At all times, clindamycin levels in mucosa were in excess of the MIC for 90% of the Helicobacter (Campylobacter) pylori strains tested.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2327758      PMCID: PMC171514          DOI: 10.1128/AAC.34.1.25

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  14 in total

1.  Campylobacter pyloridis and associated gastritis: investigator blind, placebo controlled trial of bismuth salicylate and erythromycin ethylsuccinate.

Authors:  C A McNulty; J C Gearty; B Crump; M Davis; I A Donovan; V Melikian; D M Lister; R Wise
Journal:  Br Med J (Clin Res Ed)       Date:  1986-09-13

2.  Will antibacterial chemotherapy be efficacious for gastritis and peptic ulcer?

Authors:  C S Goodwin; J A Armstrong
Journal:  J Antimicrob Chemother       Date:  1986-01       Impact factor: 5.790

3.  Relation of Campylobacter pyloridis to gastritis and peptic ulcer.

Authors:  G E Buck; W K Gourley; W K Lee; K Subramanyam; J M Latimer; A R DiNuzzo
Journal:  J Infect Dis       Date:  1986-04       Impact factor: 5.226

4.  Unidentified curved bacilli on gastric epithelium in active chronic gastritis.

Authors:  J R Warren; B Marshall
Journal:  Lancet       Date:  1983-06-04       Impact factor: 79.321

5.  Treatment failure of ofloxacin in Campylobacter pylori infection.

Authors:  Y Glupczynski; M Labbe; A Burette; M Delmee; V Avesani; C Bruck
Journal:  Lancet       Date:  1987-05-09       Impact factor: 79.321

6.  Some observations on the penetration of antibiotics through mucus in vitro.

Authors:  B A Saggers; D Lawson
Journal:  J Clin Pathol       Date:  1966-07       Impact factor: 3.411

7.  [Campylobacter pylori, gastritis and peptic ulcer].

Authors:  A M Hirschl; G Stanek; M Rotter; R Pötzi; A Gangl; E Hentschel; K Schütze; H J Holzner; H Nemec
Journal:  Wien Klin Wochenschr       Date:  1987-07-17       Impact factor: 1.704

8.  Clindamycin uptake by human neutrophils.

Authors:  M S Klempner; B Styrt
Journal:  J Infect Dis       Date:  1981-11       Impact factor: 5.226

9.  The minimum inhibitory and bactericidal concentrations of antibiotics and anti-ulcer agents against Campylobacter pyloridis.

Authors:  C S Goodwin; P Blake; E Blincow
Journal:  J Antimicrob Chemother       Date:  1986-03       Impact factor: 5.790

10.  Campylobacter pyloridis and gastritis: association with intercellular spaces and adaptation to an environment of mucus as important factors in colonization of the gastric epithelium.

Authors:  S L Hazell; A Lee; L Brady; W Hennessy
Journal:  J Infect Dis       Date:  1986-04       Impact factor: 5.226

View more
  10 in total

1.  In vitro susceptibility of Helicobacter pylori to the new oral cephalosporins cefpodoxime, ceftibuten and cefixime.

Authors:  T U Westblom; S Gudipati; B R Midkiff
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-09       Impact factor: 3.267

2.  Excretion of ciprofloxacin into the large bowel of the rabbit.

Authors:  J Ramon; S Dautrey; R Farinoti; C Carbon; E Rubinstein
Journal:  Antimicrob Agents Chemother       Date:  1996-01       Impact factor: 5.191

3.  In vitro assessment of gastric mucosal transfer of anti-Helicobacter therapeutic agents.

Authors:  A F Goddard; R C Spiller
Journal:  Antimicrob Agents Chemother       Date:  1997-06       Impact factor: 5.191

4.  Use of cryomicrotomy to study gastric diffusion of amoxicillin in guinea pigs.

Authors:  A Lozniewski; M Weber; J D De Korwin; M C Conroy; P Franck; J Floquet; A Le Faou; J C Burdin
Journal:  Antimicrob Agents Chemother       Date:  1995-03       Impact factor: 5.191

5.  Gastric penetration of amoxicillin in a human Helicobacter pylori-infected xenograft model.

Authors:  A Lozniewski; A Duprez; C Renault; F Muhale; M C Conroy; M Weber; A Le Faou; F Jehl
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

6.  Intestinal elimination of ciprofloxacin in rabbits.

Authors:  J Ramon; S Dautrey; R Farinoti; C Carbon; E Rubinstein
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

7.  In vitro susceptibility of Helicobacter pylori to trospectomycin, pirlimycin (U-57930E), mirincamycin (U-24729A) and N-demethyl clindamycin (U-26767A).

Authors:  T U Westblom; B R Midkiff; S J Czinn
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-07       Impact factor: 3.267

8.  Enhancement of antibiotic concentrations in gastric mucosa by H2-receptor antagonist. Implications for treatment of Helicobacter pylori infections.

Authors:  T U Westblom; D E Duriex
Journal:  Dig Dis Sci       Date:  1991-01       Impact factor: 3.199

9.  Mucoadhesive microspheres containing amoxicillin for clearance of Helicobacter pylori.

Authors:  N Nagahara; Y Akiyama; M Nakao; M Tada; M Kitano; Y Ogawa
Journal:  Antimicrob Agents Chemother       Date:  1998-10       Impact factor: 5.191

10.  Formulation and In Vitro evaluation of pH sensitive oil entrapped polymeric blended gellan gum buoyant beads of clarithromycin.

Authors:  G Tripathi; S Singh
Journal:  Daru       Date:  2010       Impact factor: 3.117

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.